This is a cancer that starts in the plasma cells, which are a type of white blood cell. These cells normally help fight infection, but in multiple myeloma, they grow out of control and produce abnormal proteins. This can lead to anemia (low red blood cells), high calcium levels, kidney problems, and bone damage.
Every report comes from a Lived member, sent anonymously.
Have you tried Revlimid (Lenalidomide) for Multiple Myeloma?
Multiple myeloma is a cancer of plasma cells, the white blood cells in the bone marrow that normally make antibodies to fight infection. In myeloma, abnormal plasma cells multiply in the marrow of many bones. They crowd out the cells that make healthy blood, weaken the surrounding bone, and release large amounts of a single, useless antibody called M protein (monoclonal protein), which can build up in the blood and damage the kidneys. Those effects explain the typical symptoms: bone pain, most often in the back, ribs or hips; bones that break after a minor strain; tiredness and breathlessness from anemia (too few red blood cells); frequent infections; and thirst, constipation or confusion when damaged bone releases too much calcium into the blood. Some people have no symptoms at all, and the disease is first noticed on a routine blood or urine test. Myeloma sits at the end of a spectrum. Monoclonal gammopathy of undetermined significance (MGUS) means a small amount of M protein with no cancer and no organ damage; each year about 1% of people with MGUS go on to develop myeloma or a related condition. Smoldering myeloma involves more abnormal cells or protein but still no symptoms or organ damage. Active myeloma is the stage that is causing harm, or is about to, and needs treatment.
No one knows exactly why plasma cells turn into myeloma cells. Myeloma usually develops from MGUS, which can be present for years without anyone knowing, and the risk rises steadily with age. Most people are diagnosed in their 60s or later, and the median age at diagnosis in the United States is 69. Myeloma is more common in men and in Black Americans, and it can run in families. A personal history of MGUS or of a single plasma cell tumor (a plasmacytoma), and exposure to radiation or certain chemicals, also raise the risk. These are risk factors rather than causes: most people who have them never develop myeloma, and many people with myeloma have none of them.
Myeloma is often suspected after routine blood work shows anemia, high calcium, reduced kidney function or unusually high protein, or after a fracture with no clear cause. Blood and urine tests then look for M protein and for free light chains, small fragments of the antibody that myeloma cells release (in urine these are sometimes called Bence Jones protein). A bone marrow biopsy, in which a needle removes a small sample of marrow and bone from the hip after the skin is numbed, shows what share of marrow cells are abnormal plasma cells. Imaging such as X-rays, CT, MRI or PET-CT looks for areas of damaged bone. The diagnosis of active myeloma needs two things. First, at least 10% of the marrow cells are abnormal plasma cells, or a biopsy confirms a plasma cell tumor. Second, there is evidence that the disease is causing harm: high calcium, kidney damage, anemia or bone damage (doctors call these CRAB features), or a marker that predicts harm soon, such as abnormal plasma cells making up 60% or more of the marrow, a free light chain ratio of 100 or higher, or more than one area of bone damage on MRI. When the abnormal cells are present without these signs of harm, the result is smoldering myeloma or MGUS instead. The marrow sample is also tested for specific chromosome changes. Some of them mark high-risk myeloma, which tends to grow faster and affects treatment choices. Blood levels of two proteins, albumin and beta-2 microglobulin, help assign a stage from I to III.
Treatment depends on the stage, a person's age and overall fitness, and the chromosome findings. MGUS and most smoldering myeloma are monitored with regular blood tests rather than treated, because many people never progress and treatment has real side effects. For smoldering myeloma at high risk of turning active, specialists may suggest a few years of daratumumab (Darzalex), an antibody that targets myeloma cells, to delay that change. Active myeloma is treated with combinations of medicines that attack myeloma cells in different ways. A common first treatment uses four drugs together: an antibody that targets myeloma cells, such as daratumumab; bortezomib, a proteasome inhibitor that stops myeloma cells from clearing away damaged proteins; lenalidomide (Revlimid), a capsule that acts on both the myeloma cells and the immune system; and dexamethasone, a steroid. People who are frail and cannot have a transplant usually receive a three-drug combination instead. For people fit enough, this initial treatment is followed by high-dose chemotherapy and an autologous stem cell transplant, in which the person's own blood-forming stem cells, collected earlier, are returned to rebuild the marrow. Some people with standard-risk disease can choose to delay the transplant until the myeloma returns. Afterward, maintenance treatment, usually lenalidomide combined with an antibody, helps keep the disease under control for longer. Myeloma usually comes back at some point, and there are now many further options. These include other drug combinations, CAR T-cell therapy (a person's own immune cells reprogrammed in a laboratory to attack myeloma) and bispecific antibodies, which bring immune cells and myeloma cells together so the immune cells can destroy them. Clinical trials are worth asking about at any stage. Supportive care is part of treatment, not an extra. Bone-strengthening medicines (bisphosphonates or denosumab) slow bone loss and reduce pain, radiation can relieve a painful area of bone, and treating anemia, infections and kidney problems keeps people well enough to continue therapy. The main trade-offs of drug treatment are lower blood counts with a higher risk of infection, nerve damage causing numbness or tingling in the hands and feet (particularly with bortezomib), and blood clots with lenalidomide. Lenalidomide can also cause severe birth defects, so it is available only through a restricted program with strict pregnancy prevention requirements.
For most people, myeloma is a long-term illness managed in phases rather than cured by a single course of treatment. Treatment often brings it under control for long stretches, with periods of remission between relapses, and each relapse is usually treated with a different combination. Outcomes have improved considerably: in the United States about 64% of people are alive five years after diagnosis, and myeloma death rates have been falling about 3% a year. These figures are averages across large groups. Age, kidney function, the chromosome findings and how well the disease responds to first treatment say more about any one person's outlook. Living with myeloma usually means regular clinic visits for injections or infusions, tablets or capsules taken at home, and frequent blood tests. The M protein or light chain level works as a running measure of how active the myeloma is, so a rising level can show a relapse before symptoms return. Fatigue, bone pain and a tendency to infections are common burdens, and a transplant means a period of intensive treatment and recovery. Follow-up continues for life, even during long remissions, and the team adjusts treatment as side effects, other health problems and personal priorities change.
See a doctor about bone pain that persists, especially in the back or ribs, a bone that breaks after a minor injury, ongoing unexplained tiredness or weight loss, or infections that keep coming back. If you have MGUS or smoldering myeloma, keep up with the scheduled blood tests, since they are how progression is caught before it causes damage. Call the care team promptly for fever, chills or other signs of infection during treatment, because infections in people with myeloma can become serious quickly. Also call promptly for possible signs of high calcium: extreme thirst, urinating much more than usual, new constipation or unusual drowsiness. Sudden severe back pain, or new numbness or weakness in the legs, can mean a weakened bone in the spine is pressing on the spinal cord. This is a medical emergency: contact your doctor right away or go to the emergency room. Stroke-like signs (weakness on one side of the body or slurred speech), or sudden or severe confusion, including being hard to wake, need emergency care: call 911. These signs can come from blood made too thick by M protein, from very high calcium or from a stroke itself, a risk that some myeloma treatments raise, and only an emergency assessment can tell them apart.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Multiple Myeloma is like, what's helped you, or ask the community a question.